vs

Side-by-side financial comparison of Ibotta, Inc. (IBTA) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Ibotta, Inc. is the larger business by last-quarter revenue ($88.5M vs $70.6M, roughly 1.3× Viridian Therapeutics, Inc.\DE). On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -10.0%). Ibotta, Inc. produced more free cash flow last quarter ($20.3M vs $-84.7M).

Ibotta, Inc. is an American mobile technology company headquartered in Denver, Colorado. Founded in 2011, the company offers cash back rewards on various purchases through its Ibotta Performance Network and direct to consumer app. Ibotta partners with CPG brands and network publishers to provide these rewards. As of 2024, the company operates solely in the United States. The company's rewards-as-a-service offering, the Ibotta Performance Network, went live in 2022.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

IBTA vs VRDN — Head-to-Head

Bigger by revenue
IBTA
IBTA
1.3× larger
IBTA
$88.5M
$70.6M
VRDN
Growing faster (revenue YoY)
VRDN
VRDN
+81968.2% gap
VRDN
81958.1%
-10.0%
IBTA
More free cash flow
IBTA
IBTA
$105.0M more FCF
IBTA
$20.3M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IBTA
IBTA
VRDN
VRDN
Revenue
$88.5M
$70.6M
Net Profit
$-34.6M
Gross Margin
78.7%
Operating Margin
-1.9%
-56.7%
Net Margin
-49.0%
Revenue YoY
-10.0%
81958.1%
Net Profit YoY
54.9%
EPS (diluted)
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBTA
IBTA
VRDN
VRDN
Q4 25
$88.5M
Q3 25
$83.3M
$70.6M
Q2 25
$86.0M
Q1 25
$84.6M
Q4 24
$98.4M
Q3 24
$98.6M
Q2 24
$87.9M
Q1 24
$82.3M
Net Profit
IBTA
IBTA
VRDN
VRDN
Q4 25
Q3 25
$1.5M
$-34.6M
Q2 25
$2.5M
Q1 25
$555.0K
Q4 24
Q3 24
$17.2M
Q2 24
$-34.0M
Q1 24
$9.3M
Gross Margin
IBTA
IBTA
VRDN
VRDN
Q4 25
78.7%
Q3 25
79.4%
Q2 25
79.2%
Q1 25
79.8%
Q4 24
84.6%
Q3 24
87.7%
Q2 24
86.0%
Q1 24
87.2%
Operating Margin
IBTA
IBTA
VRDN
VRDN
Q4 25
-1.9%
Q3 25
2.8%
-56.7%
Q2 25
1.4%
Q1 25
-3.3%
Q4 24
13.2%
Q3 24
21.0%
Q2 24
-24.6%
Q1 24
19.3%
Net Margin
IBTA
IBTA
VRDN
VRDN
Q4 25
Q3 25
1.8%
-49.0%
Q2 25
2.9%
Q1 25
0.7%
Q4 24
Q3 24
17.5%
Q2 24
-38.6%
Q1 24
11.3%
EPS (diluted)
IBTA
IBTA
VRDN
VRDN
Q4 25
$-0.03
Q3 25
$0.05
Q2 25
$0.08
Q1 25
$0.02
Q4 24
$3.04
Q3 24
$0.51
Q2 24
$-1.32
Q1 24
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBTA
IBTA
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$186.6M
$490.9M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$287.7M
$503.0M
Total Assets
$525.9M
$577.1M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBTA
IBTA
VRDN
VRDN
Q4 25
$186.6M
Q3 25
$223.3M
$490.9M
Q2 25
$250.5M
Q1 25
$297.1M
Q4 24
$349.3M
Q3 24
$341.3M
Q2 24
$317.9M
Q1 24
$79.5M
Total Debt
IBTA
IBTA
VRDN
VRDN
Q4 25
$0
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$65.3M
Stockholders' Equity
IBTA
IBTA
VRDN
VRDN
Q4 25
$287.7M
Q3 25
$329.6M
$503.0M
Q2 25
$354.1M
Q1 25
$401.3M
Q4 24
$457.3M
Q3 24
$378.0M
Q2 24
$359.7M
Q1 24
$44.1M
Total Assets
IBTA
IBTA
VRDN
VRDN
Q4 25
$525.9M
Q3 25
$569.4M
$577.1M
Q2 25
$600.8M
Q1 25
$639.3M
Q4 24
$678.4M
Q3 24
$598.3M
Q2 24
$556.0M
Q1 24
$322.1M
Debt / Equity
IBTA
IBTA
VRDN
VRDN
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBTA
IBTA
VRDN
VRDN
Operating Cash FlowLast quarter
$27.8M
$-84.6M
Free Cash FlowOCF − Capex
$20.3M
$-84.7M
FCF MarginFCF / Revenue
22.9%
-120.1%
Capex IntensityCapex / Revenue
8.5%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$75.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBTA
IBTA
VRDN
VRDN
Q4 25
$27.8M
Q3 25
$21.8M
$-84.6M
Q2 25
$25.9M
Q1 25
$19.9M
Q4 24
$22.0M
Q3 24
$39.5M
Q2 24
$35.0M
Q1 24
$19.4M
Free Cash Flow
IBTA
IBTA
VRDN
VRDN
Q4 25
$20.3M
Q3 25
$14.5M
$-84.7M
Q2 25
$22.2M
Q1 25
$18.0M
Q4 24
$21.8M
Q3 24
$39.2M
Q2 24
$34.8M
Q1 24
$19.2M
FCF Margin
IBTA
IBTA
VRDN
VRDN
Q4 25
22.9%
Q3 25
17.4%
-120.1%
Q2 25
25.8%
Q1 25
21.2%
Q4 24
22.1%
Q3 24
39.8%
Q2 24
39.6%
Q1 24
23.3%
Capex Intensity
IBTA
IBTA
VRDN
VRDN
Q4 25
8.5%
Q3 25
8.7%
0.2%
Q2 25
4.2%
Q1 25
2.2%
Q4 24
0.2%
Q3 24
0.3%
Q2 24
0.2%
Q1 24
0.2%
Cash Conversion
IBTA
IBTA
VRDN
VRDN
Q4 25
Q3 25
14.19×
Q2 25
10.38×
Q1 25
35.78×
Q4 24
Q3 24
2.29×
Q2 24
Q1 24
2.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBTA
IBTA

Redemption Revenue$78.5M89%
Ad Other Revenue$10.0M11%
Breakage$2.1M2%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons